Supplementary methods

Search strategy: In Scopus, we retrieved results from both "documents" and "secondary documents" tabs.

Data selection: to ensure mutual agreement, MR and PS iteratively performed consistency checks on 20 randomly selected studies prior to the selection process, until they reached 90% of agreement. The selection process consisted in the application of the inclusion criteria from the PICO scheme following a two-step process, first on the basis of title and abstract, and then on full-text. The raters were blind to each other's decisions. The first step resulted in a total of 192 disagreements, which were resolved on the basis of information from the abstracts. The raters commented and double-checked each conflicting judgement until an agreement was reached. The same strategy was used for resolving the disagreements in the full-text selection.

Data extraction: when scores of interest were reported separately across variables irrelevant for our purpose, we computed weighted means and pooled standard deviations. In studies reporting several experiments from the same sample, we computed mean scores and pooled standard deviations, resulting in one score for each variable of interest per study. On the contrary, studies reporting scores from different population samples were considered as if they were independent experiments.

Clinical scores: Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) scores were transformed into PANSS equivalent scores according to the recommended formulae (Leucht et al., 2013; van Erp et al., 2014). We had further pre-registered the extraction of confidence bias (mean confidence), depression, insight, psychosocial functioning scores, and brief psychosis episode, but did not proceed due to too few studies reporting them (N = 9, N = 4, N = 6, N = 5, and N = 7, respectively).

Formulation of the meta-analytic model:

Let ES be the observed effect sizes:

 $ES_i \sim Normal(\mu_i, \sigma_i)$

 $\mu_i = \alpha + \alpha_{study[i]}$

α ~ Normal(-0.3, 1)

 $\alpha_{studv[i]} \sim Normal(0, \tau)$

r ~ Half-Cauchy(0.1)

Where μ_i indicates the effect size of study *i*, and σ_i^2 is the known variance of the effect in study *i*.

 α is the intercept parameter of the model (the average effect size in the population). We chose a random-effect model rather than a fixed-effect model as the distributions of effect sizes are expected to be heterogeneous for metacognition in schizophrenia. Because metacognitive deficit in schizophrenia is commonly described, we specified a mildly informative prior corresponding to a metacognitive deficit with small to medium effect-size, and r^2 is the between-studies variance, provided with a mildly informative prior. Because studies with multiple experiments were rare (4 in total), we could not add experiment in addition to study as a random factor in our model.

Computation of the effect sizes (Hedge' g):

Effect sizes were computed as Hedge's G with the R package esc (Lüdecke, 2018) using the procedure given in Borenstein et al. (2010) as follows:

$$g = J \times \frac{mean_p - mean_c}{sd_{pooled}}$$

where mean_p is the average meta-performance reported for the patient group of size n_p , and mean_c is the average meta-performance reported for the control group of size n_c .

*sd*_{pooled} is the pooled standard deviation within both groups:

$$sd_{pooled} = \sqrt{\frac{(n_p - 1)sd_p^2 + (n_c - 1)sd_c^2}{n_p + n_c - 2}}$$

with sd_p the standard deviation of the meta-performance reported for the patient group, and sd_c the standard deviation for the control group.

The correction factor J to achieve an unbiased estimator is defined as:

$$J = 1 - \frac{3}{4(n_p + n_c - 2) - 1}$$

Finally, the variance of g is defined as:

$$var(g) = J^{2} \cdot \left[\frac{n_{p} + n_{c}}{n_{p}n_{c}} + \frac{1}{2(n_{p} + n_{c})} \left(\frac{mean_{p} - mean_{c}}{sd_{pooled}} \right)^{2} \right]$$

Hypothesis testing: we assessed the relative evidence toward H0 (absence of metacognitive deficit in schizophrenia) versus H1 (presence of metacognitive deficit in schizophrenia) by computing the ratio of the marginal likelihoods of each hypothesis (i.e., a Bayes factor or BF_{10}). We used the interpretation of BF_{10} given by Wagenmakers et al. (2018), which translates continuous BF_{10} values into a categorical scheme. Thus, we considered the relative strength of evidence for hypothesis H1 over H0, to be anecdotal if the BF_{10} was \in [1, 3], moderate if \in [3, 10], strong if \in [10, 30], very strong if \in [30, 100] and extremely strong if > 100.

For subgroup analyses, we retrieved the statistics (mean and 95% Crl) of the difference between the two posterior distributions obtained in each group. Then we assessed in each case under which hypothesis (H0: absence of deficit or H1: existence of a deficit) the data was the most plausible. To assess the extent to which metacognitive performance was contaminated by first-order performance in studies which did not control for it, we fitted a meta-regression model identical to M1 with the z-scores of first-order performance as an additional continuous regressor. Based on the literature (Faivre et al., 2020), we specified an informative Gaussian prior (m = 0.56, sd = 0.24) for the slope of the meta-regression.

Risk of bias: The risk of bias regarding selection, comparability and outcome was assessed in parallel by two raters (MR and PS) and intraclass correlation (ICC) scores of agreement were computed with the R package irr (Gamer et al., 2012)

Supplementary results

We assessed whether our selection of studies contained any extreme effect size values via a leave-one-out sensitivity analysis, which computes the effect sizes for each fold of n-1 studies, with n the total number of selected studies. This analysis revealed a strongly deviant study driving the overall effect size 4 standard deviations above the mean (Fig S1). This study was therefore excluded.




Figure S1: Effect size for each fold of n-1 studies. The horizontal red solid line indicates the average effect size, the dashed red line is four standard deviations above the mean. The vertical grey dashed line points to the deviant article, which has been excluded from our analysis.

Faivre 2019	0.17 [-0.36, 0.72]
Powers_b 2017	0.17 [0.00, 0.72]
Bacon 2001	0.02 [-0.52, 0.58]
Peters 2007	
Jones 2020	-0.1 [-0.3, 0.11]
Balzan 2016	
Dietrichkeit 2020	-0.17 [-0.66, 0.31]
Pinkham 2018	-0.18 [-0.62, 0.26]
Powers_a 2017	-0.18 [-0.78, 0.42]
Wright 2020	-0.26 [-0.61, 0.08]
Akdogan 2014	-0.32 [-0.83, 0.18]
Moritz 2012	-0.36 [-0.85, 0.13]
Kother 2012	-0.44 [-0.83, -0.04]
Gaweda_b 2015	-0.46 [-1.13, 0.23]
Gaweda 2019	-0.51 [-0.95, -0.06]
Gaweda_a 2015	-0.51 [-1.11, 0.09]
Metcalfe 2012	-0.53 [-1.06, 0]
Kim 2010	-0.55 [-1.19, 0.09]
Peters 2012	-0.59 [-0.97, -0.2]
Davies 2018	-0.59 [-1.1, -0.07]
Alkan 2019	-0.63 [-1.14, -0.11]
Eifler 2015	-0.65 [-1.13, -0.16]
Kircher 2007	-0.67 [-1.19, -0.15]
Moritz_W_Raecke 2006	-0.68 [-1.13, -0.24]
Gaweda 2018	-0.71 [-1.19, -0.23]
Berna 2019	
Moritz 2005	-0.72 [-1.26, -0.19]
Charles 2017	-0.72 [-1.80, -0.13]
Mayer 2018	
Mayer 2010 Moritz 2014	
Jia 2020	
Gaweda 2013	
Mayer 2012	
Moritz 2004	-0.87 [-1.43, -0.32]
Moritz&Woodward 2006	-0.94 [-1.37, -0.52]
Bhatt 2010	-0.96 [-1.5, -0.42]
Moritz_W_Chen 2006	-0.96 [-1.53, -0.41]
Moritz 2003	-0.98 [-1.5, -0.46]
Mayer 2014	-0.99 [-1.48, -0.51]
Moritz 2008	-1.04 [-1.49, -0.6]
Peters 2013	-1.07 [-1.6, -0.56]
Gaweda 2012	-1.08 [-1.56, -0.6]
Eisecher 2015	-1.23 [-1.75, -0.7]
Kother 2018	-2.66 [-3.53, -1.84]
Summary Effect Size	-0.63 [-0.82, -0.45]
	-4 -2 0
	Hedge's G Effect Size

Figure S2: Forest plot of the metacognitive deficit in schizophrenia including the outlier study. Left: Authors with publication year; Middle: posterior distribution of the effect size; Right: mean and 95% Crl of the posterior distribution. The summary effect size is displayed on the last row: the solid vertical grey line is centred on zero (i.e., equivalent metacognitive performance between groups), and the dashed vertical lines depict the boundaries of the 95% Crl.

Robustness analysis

To assess the influence of our choice of prior on effect size estimates, we re-ran the model M1 with a set of different priors α varying in mean and SD (Fig.S3). Except for very informative priors (SD = 0.1), results were robust to prior variations, in support of our main findings.




Figure S3: Metacognitive deficit effect size estimated by M1 with priors α varying in means (x-axis) and SDs (0.1: red; 1: green; 3: cyan; 10: purple).

The analysis of the moderating role of first-order performance was motivated by a significant moderation factor (Qbetween = 6.07, df = 1, p = .014), which means that the effect size was related to the control of first-order performance. Regarding subgroup analyses, l^2 for the non-controlled and controlled sub-groups were 0.65 and 0.65, corresponding to a reduction of 1.52% compared to l^2 across all studies. Q-statistic remained significant for the non-controlled and controlled sub-groups. We assessed the influence of performance-matching with a model identical to M1 including performance-matching as an additional binary predictor, with a Gaussian prior centered on -0.3 (SD = 1).

To examine the correlation between cognitive and metacognitive deficits among studies which did not control for first-order performance between groups, we performed a meta-regression by adding the standardized cognitive deficit as a continuous predictor to the model M1. On the basis of a previous study (Faivre et al., 2020), we specified a Normal prior with mean = 0.56 and SD = 0.24 for the slope parameter (the value of 0.24 corresponded to 0.1 before standardization). The mean slope value was b = 0.15, 95% CrI [-0.003, 0.30], with 97.3% of the slope estimates above 0, and very strong evidence in support of our hypothesis for a positive relationship between cognitive and metacognitive deficits (BF₁₀ = 36). Although a prior with SD = 0.24 is quite informative, the robustness analysis revealed stable patterns for a prior with mean = 0.56 (Fig.S5).




Figure S4: Meta-regression of the metacognitive deficit as a function of the cognitive deficit for studies which do not control for first-order performance. Each data point corresponds to one study (N = 33).

Robustness analysis




Figure S5: Slope estimates for the relationship between cognitive and metacognitive deficits under priors varying in means (x-axis, 0.73 and 2.44 corresponding to 0.3 and 1, respectively, after standardisation) and SDs (0.24: red; 2.44: green; 24.37: blue, corresponding to 0.1, 1, 10, respectively, after standardisation). The vertical red dashed line indicates the prior's mean value specified in our analysis.

Regarding metacognitive deficits across cognitive domains, I² for the memory, perception and other domain sub-groups were 0.52, 0.64 and 0 respectively, corresponding to a reduction of 21%, 3%, and 100% compared to the global analysis. Q-statistic remained significant for the memory and perception sub-groups. We performed a sub-group analysis with a weakly informative prior with mean = -0.3, and SD = 1 for the effect of cognitive domains. We found extremely strong evidence supporting a greater influence of memory vs. perception studies on the metacognitive deficit (m = -0.38, 95% CrI [-0.66, -0.09], BF₁₀ = 203). This pattern was even more pronounced when memory was compared with other domains (social and agency; m = -0.49, 95% CrI [-0.83, -0.12], BF₁₀ = 182).

Finally, we performed meta-regressions between the metacognitive deficits and clinical variables, with a prior of mean 0 and SD = 1. We had pre-registered the hypothesis of a

negative correlation between meta-performance and PANSS positive scores. However, meta-regression analyses provided inconclusive evidence regarding the influence of symptom severity on the metacognitive deficit: $BF_{01} = 1.14$ for PANSS total scores (N = 35), $BF_{01} = 1.11$ for PANSS positive scores (N = 33) and $BF_{01} = 1.38$ for PANSS negative scores (N = 34). Similarly, we found no evidence for an association between metacognitive performance and pharmacological treatment (N = 21), with an evidence ratio ($BF_{01} = 1.01$) suggesting inconclusive data (Fig. S6).




Figure S6: Meta-regressions of the metacognitive deficit with PANSS total scores (A), PANSS positive scores (B), PANSS negative scores (C), and antipsychotic dosage (D). The x-axes represent the posterior estimates for the slope parameter. Posterior and prior distributions are depicted in dark gray and light gray, respectively.

Similar results were found between first-order cognitive deficits and clinical features (Fig. S7) : $BF_{01} = 1.08$ for PANSS total scores (N = 35), $BF_{01} = 1.34$ for PANSS positive scores (N = 33), $BF_{01} = 1.35$ for PANSS total scores (N = 34), $BF_{01} = 1.01$ for PANSS total scores (N = 21).




Figure S7: Meta-regressions of the cognitive deficit with PANSS total scores (A), PANSS positive scores (B), PANSS negative scores (C), and antipsychotic dosage (D). The x-axes represent the posterior estimates for the slope parameter. Posterior and prior distributions are depicted in dark gray and light gray, respectively.

The risk of bias was assessed using the Newcastle Ottawa Scale. The total ICC score (two way model, agreement type, single unit) revealed an average agreement between the two raters (MR and PS) of 0.55 according to interpretation schemes given by Koo & Li (2016). We then targeted the studies for which there were more than two divergences out of nine between the two raters. The six studies which reached this criterion were assessed again by two others raters (NF and PR). For these six studies, the final NOS score was obtained by averaging the scores given MR, PS, NF and PR.

About half of the studies included in this meta-analysis were rated as poor according to the interpretation scheme provided by the Newcastle Ottawa Scale (Fig. S8-9).




Figure S8: NOS quotation for each article included in the present meta-analysis




Figure S9 : The nine NOS items are presented on the x-axis: 1: Case definition adequacy, 2: Case representativeness, 3: Control selection, 4: Definition of controls, 5: Control for first-order performance between groups, 6: Control for Age/QI between groups, 7: Computerized protocol, 8: Same protocol for both groups, 9: Non-response rate. The y-axis represents the total number of articles which were granted a point for each NOS item.

Study	PANSS (total)	PANSS (positive)	PANSS (negative)	Chlorpromazine (mg)	Manual
Akdogan 2014	69 ± 27.8	14.9 ± 4.6	18.8 ± 10.5	Not reported	DSM4-TR
Alkan 2019	Not reported	5.24 ± NA	5.76 ± NA	264.8 ± NA	Not reported
Bacon 2001	67.62 ± 11.5	44.76 ± 16	54.48 ± 20.3	348 ± 273	DSM3-R
Balzan 2016	11.08 ± 3.12	Not reported	Not reported	Not reported	DSM4
Berna 2019	75.13 ± 19.68	20.5 ± 5.04	17.88 ± 6.66	Not reported	DSM4-TR
Bhatt 2010	Not reported	Not reported	Not reported	Not reported	RDC
Charles 2017	Not reported	11.3 ± 3.4	15.5 ± 4.4	224.3 ± 103	DSM4
Davies 2018	Not reported	5.43 ± 2.44	5.4 ± 2.8	279.4 ± 150.2	Not reported
Dietrichkeit 2020	51.69 ± 13.02	Not reported	Not reported	Not reported	Not reported
Eifler 2015	67.41 ± 16.01	15.75 ± 5.34	16.59 ± 6.54	425.96 ± 183.68	DSM4-R
Eisecher 2015	85.67 ± 18.62	22.95 ± 5.04	18.26 ± 7.02	Not reported	DSM4
Faivre 2019	78.5 ± 12.79	17.2 ± 5.85	20.5 ± 6.44	439.7 ± 27.08	DSM5
Gaweda 2012	72 ± 13.21	13.2 ± 5.36	19.54 ± 6.89	Not reported	MINI
Gaweda 2013	62.57 ± 11.37	16.81 ± 5.43	17.81 ± 6.25	Not reported	DSM4
Gaweda 2018	87.64 ± 14.58	11.5 ± 4.3	3.72 ± 1.18	405.98 ± 175.04	DSM4
Gaweda 2019	46.81 ± 12.27	12 ± 4.9	13 ± 5.22	Not reported	DSM5
Gaweda_2015	66 ± 17.1	20.15 ± 8.07	18.23 ± 4.56	Not reported	MINI
Gaweda_2015	79.55 ± 16	23.88 ± 6.97	19.33 ± 10.13	Not reported	MINI
Jia 2020	54.6 ± 12.9	13.2 ± 5.6	14.1 ± 6.4	369 ± 397	ICD-10
Jones 2020	Not reported	Not reported	Not reported	Not reported	DSM4
Kim 2010	22.56 ± 6.6	20.4 ± 7.8	22.7 ± 10.1	Not reported	DSM4
Kircher 2007	66.4 ± 21.4	17.3 ± 7.2	17.2 ± 6.5	411 ± 257	DSM4
Kother 2012	58.28 ± 15.82	15.2 ± 8.21	14.14 ± 6.34	Not reported	MINI
Mayer 2012	20.8 ± 5.74	24.17 ± 10.23	31.1 ± 13.81	361.12 ± 381.78	DSM4
Mayer 2014	Not reported	25.33 ± 11.12	32.53 ± 14.95	329.23 ± 299.36	DSM4
Mayer 2018	31.29 ± 7.92	14.92 ± 4.27	16.17 ± 6.31	501.13 ± 265.57	DSM5
Metcalfe 2012	46.1 ± 5.8	Not reported	36.89 ± 12.2	Not reported	DSM4
Moritz 2003	63.3 ± 12.3	8.86 ± 4.4	7.62 ± 3	253.04 ± 189.7	DSM4
Moritz 2004	13.84 ± 4.51	Not reported	Not reported	676.59 ± 523.86	DSM4
Moritz 2005	17.33 ± 7.35	Not reported	Not reported	671.6 ± 494.4	DSM4
Moritz 2008	62.24 ± 18.37	Not reported	Not reported	Not reported	ICD-10
Moritz 2012	60.04 ± 11.11	Not reported	Not reported	Not reported	DSM4
Moritz 2014	Not reported	1.8 ± 0.39	2.32 ± 0.54	Not reported	Not reported
Moritz_a 2006	68.45 ± 17.48	Not reported	Not reported	687.88 ± 864.69	DSM4
Moritz_b 2006	Not reported	9.67 ± 4.2	12.77 ± 6.17	Not reported	DSM4
Moritz_c 2006	66.31 ± 16.62	Not reported	Not reported	Not reported	DSM4
Peters 2007	55.64 ± 8.52	9.17 ± 4.29	5.3 ± 2.12	Not reported	DSM4
Peters 2012	54.7 ± 13.27	14.81 ± 6.28	11.7 ± 4.94	Not reported	DSM4
Peters 2013	49.29 ± 9.75	12.66 ± 4.76	11.59 ± 4.63	368.87 ± 260.63	MINI
Pinkham 2018	30.48 ± 6.44	17.54 ± 5.68	12.23 ± 3.2	452.28 ± 416.14	MINI/SCID
Powers_2017	61.2 ± 7.94	19.67 ± 4.14	15.2 ± 4.8	431.46 ± 90.92	DSM4
Powers_2017	54.43 ± 10.33	14.93 ± 3.26	14.14 ± 4.19	330.43 ± 66.28	DSM4
Wright 2020	Not reported	12.4 ± 4.7	11.5 ± 4	Not reported	Not reported

Table S1: Summary of clinical data for each study (PANSS total, PANSS positive, PANSS negative, chlorpromazine equivalent and diagnostic tool).

References

- Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (Eds.). (2010). *Introduction to meta-analysis* (Reprinted). Wiley.
- Faivre, N., Roger, M., Pereira, M., de Gardelle, V., Vergnaud, J.-C., Passerieux, C., & Roux, P. (2020). Confidence in visual motion discrimination is preserved in individuals with schizophrenia. *Psychiatry and Clinical Neurosciences*. https://doi.org/10.1503/jpn.200022
- Gamer, M., Lemon, J., Gamer, M. M., Robinson, A., & Kendall's, W. (2012). Package 'irr'. *Various coefficients of interrater reliability and agreement*. R package version 0.84.1.
- Koo, T. K., & Li, M. Y. (2016). A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *Journal of Chiropractic Medicine*, *15*(2), 155–163. https://doi.org/10.1016/j.jcm.2016.02.012
- Leucht, S., Rothe, P., Davis, J. M., & Engel, R. R. (2013). Equipercentile linking of the BPRS and the PANSS. *European Neuropsychopharmacology*, *23*(8), 956–959. https://doi.org/10.1016/j.euroneuro.2012.11.004
- Lüdecke, D. (2018). Esc: Effect Size Computation For Meta Analysis. Zenodo. https://doi.org/10.5281/ZENODO.1249218
- van Erp, T. G. M., Preda, A., Nguyen, D., Faziola, L., Turner, J., Bustillo, J., Belger, A., Lim, K. O., McEwen, S., Voyvodic, J., Mathalon, D. H., Ford, J., Potkin, S. G., & Fbirn. (2014). Converting positive and negative symptom scores between PANSS and SAPS/SANS. *Schizophrenia Research*, *152*(1), 289–294. https://doi.org/10.1016/j.schres.2013.11.013
- Wagenmakers, E.-J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Love, J., Selker, R., Gronau, Q. F., Šmíra, M., Epskamp, S., Matzke, D., Rouder, J. N., & Morey, R. D. (2018).
 Bayesian inference for psychology. Part I: Theoretical advantages and practical ramifications. *Psychonomic Bulletin & Review*, 25(1), 35–57. https://doi.org/10.3758/s13423-017-1343-3